Found 7 articles for: "adverse events"
Latin America Cutaneous Oncology Management (LACOM) II: A Practical Algorithm for Managing Skin Toxicities in Oncology Patients
July 2026 | Volume 25 | Issue 7 | Original Article | 621 | Copyright © July 2026
Background: Anticancer treatments are associated with cutaneous adverse events (cAEs) that can severely impact patients' quality of life (QoL) and interfere with treatment outcom...
Read MoreCutaneous Adverse Effects of Hormonal and HER2-Targeted Therapies in Breast Cancer Patients: A Case Series
July 2026 | Volume 25 | Issue 7 | Case Reports | 659 | Copyright © July 2026
Background: Aromatase inhibitors (AIs) and anti-HER2 therapies improve breast cancer survival, but dermatologic adverse events (dAEs) are underrecognized despite affecting qualit...
Read MoreLonger Pembrolizumab Therapy Reduces Mortality in Stage III and IV Melanoma: A TriNetX Study
May 2026 | Volume 25 | Issue 5 | Original Article | 421 | Copyright © May 2026
Background: Melanoma is the leading cause of skin-cancer-related mortality worldwide. Anti-programmed cell death protein-1 therapies, including pembrolizumab, play a critical rol...
Read MoreThe Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma
May 2025 | Volume 24 | Issue 5 | Features | 539 | Copyright © May 2025
Background: Melanoma continues to remain one of the most feared malignancies among patients and dermatologists. Significant strides have been made in expanding the treatment arse...
Read MoreCutaneous Immune-Related Adverse Events Associated With Immunotherapy in Patients With Melanoma
May 2025 | Volume 24 | Issue 5 | Original Article | 490 | Copyright © May 2025
Background: Cutaneous immune-related adverse events (irCAEs) have been commonly reported as a consequence of immune checkpoint inhibitors (ICIs) for the treatment of advanced sta...
Read MoreA Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies
April 2025 | Volume 24 | Issue 4 | Features | 413 | Copyright © April 2025
Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack o...
Read MoreLatin America Cutaneous Oncology Management (LACOM) I: The Role of Skin Care in Oncology Patients and Survivors
March 2025 | Volume 24 | Issue 3 | Original Article | 262 | Copyright © March 2025
Background: Cancer-treatment-related cutaneous adverse events (cAEs) are common and may severely impact quality of life (QoL) and decrease treatment outcomes. The Latin American ...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
